유전성 검사 시장 규모, 점유율, 동향 분석 보고서 : 질환 유형별, 기술별, 지역별, 부문별 예측(2025-2033년)

Hereditary Testing Market Summary

The global hereditary testing market size was estimated at USD 16.16 billion in 2024 and is projected to reach USD 52.66 billion by 2033, growing at a CAGR of 14.42% from 2025 to 2033, due to the increasing prevalence of genetic disorders and related chronic conditions. As more individuals are diagnosed with inherited cancers, cardiovascular diseases, metabolic syndromes, and rare genetic abnormalities, the demand for early and accurate detection has surged.

Many hereditary conditions often manifest later in life, making early testing essential for prevention, monitoring, and medical decision-making. Moreover, increased screening of newborns and infants has highlighted a substantial number of genetic abnormalities that previously went undetected. With better clinical awareness, physicians are recommending genetic testing more often as part of routine risk assessment. In addition, as populations age, age-related hereditary conditions-such as certain cancers and neurodegenerative disorders-are becoming more common, encouraging more genetic evaluations. Together, these factors drive sustained market growth by emphasizing the critical role of hereditary testing in identifying health risks before symptoms emerge.

Global Hereditary Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global hereditary testing market report on the basis of disease type, technology, and region.

• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Hereditary Cancer Testing
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Stomach/Gastric Cancer
  • Melanoma
  • Sarcoma
  • Uterine Cancer
  • Pancreatic Cancer
  • Others
• Hereditary Non-cancer Testing
  • Genetic Tests
  • Cardiac Diseases
  • Rare Diseases
  • Other Diseases
  • Preimplantation Genetic Diagnosis & Screening
  • Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
  • Newborn Genetic Screening
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cytogenetic
• Biochemical
• Molecular Testing
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Table of Contents

Chapter 1. Hereditary Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Disease Type
    • 1.1.1.2. Technology Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Hereditary Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Disease Type Technology Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hereditary Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increase in sales and demand for DNA test kits
  • 3.4.2. Constantly developing commercial landscape of women's reproductive health
  • 3.4.3. Decline in sequencing cost & consequent expansion of genetic testing registry
• 3.5. Market Restraint Analysis
  • 3.5.1. Ethical and clinical issues of DNA tests
  • 3.5.2. Regulatory challenges pertaining to use of DTC genetic tests
• 3.6. Market Opportunity Analysis
  • 3.6.1. Increasing incidence of genetic diseases
  • 3.6.2. Presence of demand for early and non-invasive fetal testing procedures
  • 3.6.3. Introduction of fragmented point-solutions across the genomics value chain
• 3.7. Porter's Five Forces Analysis
• 3.8. PESTLE Analysis
• 3.9. Pipeline Analysis

Chapter 4. Hereditary Testing Market: Disease Type Estimates & Trend Analysis

• 4.1. Hereditary Testing Market: Disease Type Movement Analysis
• 4.2. Hereditary Cancer Testing
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. Breast Cancer
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Lung Cancer
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Colorectal Cancer
    • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.5. Cervical Cancer
    • 4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.6. Ovarian Cancer
    • 4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.7. Prostate Cancer
    • 4.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.8. Stomach/Gastric Cancer
    • 4.2.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.9. Melanoma
    • 4.2.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.10. Sarcoma
    • 4.2.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.11. Uterine Cancer
    • 4.2.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.12. Pancreatic Cancer
    • 4.2.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.13. Others
    • 4.2.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Hereditary Non-cancer Testing
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Genetic Tests
    • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.2. Cardiac Diseases
      • 4.3.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.3. Rare Diseases
      • 4.3.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2.4. Other Diseases
      • 4.3.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Preimplantation Genetic Diagnosis & Screening
    • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
    • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.5. Newborn Genetic Screening
    • 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hereditary Testing Market: Technology Estimates & Trend Analysis

• 5.1. Hereditary Testing Market: Technology Movement Analysis
• 5.2. Cytogenetic
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Biochemical
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Molecular Testing
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hereditary Testing Market: Regional Business Analysis

• 6.1. Regional Market Snapshot
• 6.2. North America
  • 6.2.1. North America Hereditary Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. U.S. Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.2.2.2. Key Country Dynamics
    • 6.2.2.3. Regulatory Framework
    • 6.2.2.4. Reimbursement Scenario
    • 6.2.2.5. Competitive Scenario
  • 6.2.3. Canada
    • 6.2.3.1. Canada Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.2.3.2. Key Country Dynamics
    • 6.2.3.3. Regulatory Framework
    • 6.2.3.4. Reimbursement Scenario
    • 6.2.3.5. Competitive Scenario
  • 6.2.4. Mexico
    • 6.2.4.1. Mexico Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.2.4.2. Key Country Dynamics
    • 6.2.4.3. Regulatory Framework
    • 6.2.4.4. Reimbursement Scenario
    • 6.2.4.5. Competitive Scenario
• 6.3. Europe
  • 6.3.1. Europe Hereditary Testing Market, 2021 - 2033 (USD Million)
  • 6.3.2. UK
    • 6.3.2.1. UK Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.2.2. Key Country Dynamics
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Reimbursement Scenario
    • 6.3.2.5. Competitive Scenario
  • 6.3.3. Germany
    • 6.3.3.1. Germany Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.3.2. Key Country Dynamics
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Reimbursement Scenario
    • 6.3.3.5. Competitive Scenario
  • 6.3.4. Spain
    • 6.3.4.1. Spain Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.4.2. Key Country Dynamics
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Reimbursement Scenario
    • 6.3.4.5. Competitive Scenario
  • 6.3.5. France
    • 6.3.5.1. France Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.5.2. Key Country Dynamics
    • 6.3.5.3. Regulatory Framework
    • 6.3.5.4. Reimbursement Scenario
    • 6.3.5.5. Competitive Scenario
  • 6.3.6. Italy
    • 6.3.6.1. Italy Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.6.2. Key Country Dynamics
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Reimbursement Scenario
    • 6.3.6.5. Competitive Scenario
  • 6.3.7. Denmark
    • 6.3.7.1. Denmark Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.7.2. Key Country Dynamics
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Reimbursement Scenario
    • 6.3.7.5. Competitive Scenario
  • 6.3.8. Sweden
    • 6.3.8.1. Sweden Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.8.2. Key Country Dynamics
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Reimbursement Scenario
    • 6.3.8.5. Competitive Scenario
  • 6.3.9. Norway
    • 6.3.9.1. Norway Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.9.2. Key Country Dynamics
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Reimbursement Scenario
    • 6.3.9.5. Competitive Scenario
• 6.4. Asia Pacific
  • 6.4.1. Asia-Pacific Hereditary Testing Market, 2021 - 2033 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Japan Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.2.2. Key Country Dynamics
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Scenario
    • 6.4.2.5. Competitive Scenario
  • 6.4.3. China
    • 6.4.3.1. China Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.3.2. Key Country Dynamics
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Scenario
    • 6.4.3.5. Competitive Scenario
  • 6.4.4. India
    • 6.4.4.1. India Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.4.2. Key Country Dynamics
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Scenario
    • 6.4.4.5. Competitive Scenario
  • 6.4.5. South Korea
    • 6.4.5.1. South Korea Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.5.2. Key Country Dynamics
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Reimbursement Scenario
    • 6.4.5.5. Competitive Scenario
  • 6.4.6. Thailand
    • 6.4.6.1. Thailand Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.6.2. Key Country Dynamics
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Reimbursement Scenario
    • 6.4.6.5. Competitive Scenario
  • 6.4.7. Australia
    • 6.4.7.1. Australia Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.7.2. Key Country Dynamics
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Reimbursement Scenario
    • 6.4.7.5. Competitive Scenario
• 6.5. Latin America
  • 6.5.1. Latin America Hereditary Testing Market, 2021 - 2033 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Brazil Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.5.2.2. Key Country Dynamics
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Scenario
    • 6.5.2.5. Competitive Scenario
  • 6.5.3. Argentina
    • 6.5.3.1. Argentina Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.5.3.2. Key Country Dynamics
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Scenario
    • 6.5.3.5. Competitive Scenario
• 6.6. Middle East & Africa
  • 6.6.1. Middle East & Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. South Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.6.2.2. Key Country Dynamics
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Scenario
    • 6.6.2.5. Competitive Scenario
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Saudi Arabia Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.6.3.2. Key Country Dynamics
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Scenario
    • 6.6.3.5. Competitive Scenario
  • 6.6.4. UAE
    • 6.6.4.1. UAE Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.6.4.2. Key Country Dynamics
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Scenario
    • 6.6.4.5. Competitive Scenario
  • 6.6.5. Kuwait
    • 6.6.5.1. Kuwait Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.6.5.2. Key Country Dynamics
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Scenario
    • 6.6.5.5. Competitive Scenario

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
  • 7.2.1. New Product Launch
  • 7.2.2. Partnerships
  • 7.2.3. Acquisition
  • 7.2.4. Collaboration
  • 7.2.5. Funding
• 7.3. Key Company Market Share Analysis, 2024
• 7.4. Company Heat Map Analysis
• 7.5. Company Profiles
  • 7.5.1. Myriad Genetics, Inc.
    • 7.5.1.1. Company Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Invitae Corporation
    • 7.5.2.1. Company Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Illumina, Inc.
    • 7.5.3.1. Company Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Natera, Inc.
    • 7.5.4.1. Company Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Laboratory Corporation of America Holdings
    • 7.5.5.1. Company Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. F. Hoffmann-La Roche Ltd.
    • 7.5.6.1. Company Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Quest Diagnostics Incorporated
    • 7.5.7.1. Company Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. COOPERSURGICAL, INC.
    • 7.5.8.1. Company Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Agilent Technologies, Inc.
    • 7.5.9.1. Company Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Thermo Fisher Scientific, Inc.
    • 7.5.10.1. Company Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Twist Bioscience
    • 7.5.11.1. Company Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. SOPHiA GENETICS
    • 7.5.12.1. Company Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. Fulgent Genetics
    • 7.5.13.1. Company Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. MedGenome
    • 7.5.14.1. Company Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic Initiatives
  • 7.5.15. CENTOGENE N.V.
    • 7.5.15.1. Company Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic Initiatives